What the trials found
For clinicians
Poliomyelitis: what the trials found
Multiple inactivated poliovirus vaccine (IPV) formulations, including Poliorix, IMOVAX POLIO, and various combination vaccines such as Infanrix hexa, Boostrix-Polio, TETRAXIM, and COVAXIS, have been evaluated for polio prophylaxis. Clinical data indicate that IMOVAX POLIO achieved 98.3% to 100% seroprotection against polio antigens following booster vaccination 11. Additionally, the Sabin mOPV2 vaccine demonstrated a seroprotection rate of 47% to 50% for Type 2 Polio neutralizing antibodies 3.
Comparative studies on IPV administration show non-inferiority in seroconversion across different dosing and routes. Specifically, two doses of f-IPV ID were found non-inferior to two doses of IPV IM (98.1% vs 95.9%), three doses of IPV IM (100% vs 98.1%), and three doses of IPV ID (98.8% vs 95.9%) 15. Furthermore, nOPV2 demonstrated high seroconversion rates at 1, 2, and 4-week intervals 22.
Safety profiles for these interventions vary across trials but generally involve local and general symptoms. For example, Poliorix reported varying counts of Grade 3 solicited local and general symptoms across different study cohorts [12, 19, 20, 21], while Boostrix-Polio showed specific counts of Grade 3 solicited local symptoms in several groups [2, 5].
For the clinician treating this condition
- Multiple IPV formulations and combination vaccines (e.g., Infanrix hexa, Boostrix-Polio) are established for polio prevention with varying seroprotection profiles.
- Two doses of f-IPV ID have demonstrated non-inferiority to both two and three doses of IPV IM for seroconversion 15.
- IMOVAX POLIO showed high consistency in seroprotection (up to 100%) following booster vaccination 11.
AI synthesis of 4 cited trials,
updated Jun 28, 2026.
Informational only — not medical advice; trial data sourced from ClinicalTrials.gov.
How we use AI.
